Research programme: cannabinoid therapeutics - Zelda Therapeutics

Drug Profile

Research programme: cannabinoid therapeutics - Zelda Therapeutics

Alternative Names: Cannabinoid therapeutics - Zelda Therapeutics; Tetra-hydro cannabinoids - Zelda Therapeutics

Latest Information Update: 19 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zelda Therapeutics
  • Developer Complutense University Madrid; Telethon Kids Institute; Zelda Therapeutics
  • Class Antineoplastics; Cannabinoids; Immunotherapies; Skin disorder therapies; Sleep disorder therapies
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autistic disorder; Brain cancer; Breast cancer; Eczema; Insomnia; Pancreatic cancer

Most Recent Events

  • 12 Jan 2018 Zelda Therapeutics plans to initiate a clinical trial of cannabinoids for Autistic disorders in 2018
  • 01 Dec 2017 Preclinical trials in Autistic disorder in Australia (unspecified route)
  • 28 Nov 2017 Zelda Therapeutics plans to initiate a clinical trial of cannabis formulation for Insomnia in USA and Australia in the first quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top